On January 1, 2026, one of the most consequential shifts in outpatient care delivery in a decade took effect quietly.

The Centers for Medicare and Medicaid Services (CMS) finalized the addition of 573 codes to the ASC Covered Procedures List, making 2026 the largest single-year expansion of ASC-eligible procedures in Medicare history. For MedTech companies operating in cardiovascular, spine, vascular, and musculoskeletal specialties, this is a commercial inflection point that deserves more attention than most companies have given it.

The question worth asking now is whether your commercial model was built for the channel your buyers are moving into.

What Changed and Why It Matters

The 2026 expansion came from two simultaneous policy changes. First, CMS revised the criteria for adding procedures to the ASC Covered Procedures List, removing five regulatory exclusion criteria and shifting clinical judgment to physicians on a case-by-case basis. This change alone added 276 new procedures, concentrated in cardiovascular, spine, and vascular specialties.

Second, CMS initiated the three-year elimination of the inpatient-only list, a structural change that will be complete by January 2028. As the first step, 271 procedures were removed from inpatient-only status in 2026 and moved directly onto the ASC list, primarily musculoskeletal and orthopedic cases. Source: Holland and Knight CMS Final Rule Analysis, November 2025.

The specific procedures that now qualify for ASC reimbursement include electrophysiology studies and ablations (CPT 93650, 93653, 93654, 93656), percutaneous coronary interventions (C9602, C9604, C9607), vascular embolization and occlusion (37244), posterior lumbar interbody fusion (22630), and combined posterior and lumbar interbody fusion (22633). Source: Hall Render Legal Analysis, CMS 2026 Proposed Rule.

In a single regulatory cycle, procedures that had been confined to hospital outpatient departments became eligible for freestanding ambulatory surgery centers. For device companies whose products support these procedures, the commercial implications are immediate and require an intentional response.

The ASC Buyer Is a Different Conversation

Hospital health systems have established value analysis committees, dedicated procurement infrastructure, and multi-stakeholder buying processes. Most MedTech commercial teams have learned to navigate this environment over years of field experience. The sales cycle is long, the clinical champion is rarely the economic buyer, and the contract runs through supply chain before it reaches the OR.

The ASC buyer operates differently. Ambulatory surgery centers typically have leaner administrative structures, faster decision timelines, and purchasing authority that sits much closer to the physician. The economic and clinical buyer are often the same person, usually the ASC medical director or administrator, and the adoption conversation can move in weeks rather than months.

But the value drivers are also different. ASCs operate with tighter margins than hospital systems and are more sensitive to case efficiency, turnover time, per-case supply costs, and reimbursement alignment. A device that makes clinical sense in a hospital value analysis conversation needs a different commercial narrative to make economic sense in an ASC setting.

A commercial model built around hospital outpatient does not translate cleanly. The ICP definition, the claims matrix, the reimbursement narrative, and the channel approach all require adaptation for the ASC buyer, and companies that show up with a hospital playbook will leave credibility and opportunity on the table.

What a 2026 ASC Strategy Needs to Include

For MedTech companies in the affected specialties, four specific questions should drive the commercial strategy conversation.

First, is the ASC buyer defined in your ICP at the person level? Not ambulatory surgery centers as a channel category, but the specific decision-maker inside that channel. The medical director, the administrator, or the physician owner, with their specific budget authority, their workflow concerns, and their value drivers. The ICP that works for a health system procurement conversation will not automatically work for an ASC.

Second, does your claims matrix speak to ASC-specific value? The clinical claims that move a hospital value analysis committee may be the same claims that resonate in an ASC, but the economic claims are different. Case efficiency, scheduling flexibility, supply cost per case, and reimbursement alignment with ASC payment rates are the commercial levers that advance an ASC conversation. If your claims matrix was built entirely around hospital-facing value, it needs an ASC layer added.

Third, does your reimbursement narrative account for the ASC rate structure? CMS finalized an average 2.6 percent payment increase for ASC-covered procedures in 2026, but the ASC conversion factor at $56.21 remains significantly below the Hospital Outpatient Department rate at $91.75. Understanding how reimbursement works in the ASC setting and how to position your device's economic value within that structure is foundational to a credible commercial conversation.

Fourth, does your sales team know how to navigate an ASC buying conversation? The relationship dynamics, the decision timeline, the contracting process, and the objection patterns in an ASC are different from a hospital sale. If your commercial team was built for hospital outpatient, the ASC channel requires targeted preparation before your reps are in those rooms.

The Window to Act

SCA Health executives, commenting publicly on the 2026 expansion, noted that the real commercial impact will take time to materialize as ASCs prepare their facilities and build the necessary clinical infrastructure. That observation works in both directions.

ASCs that are moving quickly to add cardiovascular and spine capabilities are actively evaluating the device companies that can support those procedures. The MedTech companies that show up with a clear ASC value proposition, a trained sales team, and a reimbursement narrative built for the outpatient setting will have a first-mover advantage over those still running a hospital commercial playbook in a channel that has moved on.

The companies that adapt their commercial model in 2026 will be the ones their competitors are trying to displace in 2027.

If your commercial model needs to account for the ASC channel shift and you are not sure where to start, Tribe's GTM Mini-Sprint builds the ASC commercial strategy alongside your existing channel approach in 4 to 6 weeks. The One-Day Intensive is the right starting point if you want a clear diagnosis before committing to the build. tribeconsulting.co